Virginia Ponziani1, Monia Gennari1, Fabio Pizza2,3, Antonio Balsamo4, Filippo Bernardi1, Giuseppe Plazzi2,3. 1. Pediatric Unit, S. Orsola-Malpighi University Hospital, Bologna, Italy. 2. Department of Biomedical and NeuroMotor Sciences, University of Bologna, Italy. 3. IRCCS Institute of Neurological Sciences, Bellaria Hospital, Bologna, Italy. 4. Pediatric Endocrinology Unit, Center for Rare Endocrine Diseases, S. Orsola-Malpighi University Hospital, Bologna, Italy.
Abstract
STUDY OBJECTIVES: To evaluate the effect of type 1 narcolepsy (NT1) on anthropometric and endocrine features in childhood/adolescence, focusing on patterns and correlates of weight, pubertal development, and growth in treated and untreated patients. METHODS: We collected anthropometric (height, weight, body mass index (BMI) z-scores), pubertal, metabolic, and endocrine data from 72 NT1 patients at diagnosis and all available premorbid anthropometric parameters of patients from their pediatric files (n = 30). New measurements at 1-y reassessment in patients undergoing different treatments were compared with baseline data. RESULTS: We detected a high prevalence of overweight (29.2%), obesity (25%), metabolic syndrome (18.8%), and precocious puberty (16.1%), but no signs of linear growth alterations at diagnosis. According to anthropometric records, weight gain started soon after NT1 onset. At 1-y follow-up reassessment, sodium oxybate treatment was associated with a significant BMI z-score reduction (-1.29 ± 0.30, p < 0.0005) after adjusting for baseline age, sex, sleepiness, and BMI. CONCLUSIONS: NT1 onset in children/adolescents is associated with rapid weight gain up to overweight/obesity and precocious puberty without affecting growth. In our study, sodium oxybate treatment resulted in a significant weight reduction in NT1 overweight/obese patients at 1-y follow-up.
STUDY OBJECTIVES: To evaluate the effect of type 1 narcolepsy (NT1) on anthropometric and endocrine features in childhood/adolescence, focusing on patterns and correlates of weight, pubertal development, and growth in treated and untreated patients. METHODS: We collected anthropometric (height, weight, body mass index (BMI) z-scores), pubertal, metabolic, and endocrine data from 72 NT1 patients at diagnosis and all available premorbid anthropometric parameters of patients from their pediatric files (n = 30). New measurements at 1-y reassessment in patients undergoing different treatments were compared with baseline data. RESULTS: We detected a high prevalence of overweight (29.2%), obesity (25%), metabolic syndrome (18.8%), and precocious puberty (16.1%), but no signs of linear growth alterations at diagnosis. According to anthropometric records, weight gain started soon after NT1 onset. At 1-y follow-up reassessment, sodium oxybate treatment was associated with a significant BMI z-score reduction (-1.29 ± 0.30, p < 0.0005) after adjusting for baseline age, sex, sleepiness, and BMI. CONCLUSIONS: NT1 onset in children/adolescents is associated with rapid weight gain up to overweight/obesity and precocious puberty without affecting growth. In our study, sodium oxybate treatment resulted in a significant weight reduction in NT1 overweight/obesepatients at 1-y follow-up.
Authors: Claire E H M Donjacour; N Ahmad Aziz; Ferdinand Roelfsema; Marijke Frölich; Sebastiaan Overeem; Gert Jan Lammers; Hanno Pijl Journal: Am J Physiol Endocrinol Metab Date: 2011-03-29 Impact factor: 4.310
Authors: E Ghigo; J Bellone; G Aimaretti; S Bellone; S Loche; M Cappa; E Bartolotta; F Dammacco; F Camanni Journal: J Clin Endocrinol Metab Date: 1996-09 Impact factor: 5.958
Authors: Sebastiaan Overeem; Simon W Kok; Gert Jan Lammers; Alla A Vein; Marijke Frölich; Arend E Meinders; Ferdinand Roelfsema; Hanno Pijl Journal: Am J Physiol Endocrinol Metab Date: 2002-11-26 Impact factor: 4.310
Authors: Marco Filardi; Fabio Pizza; Elena Antelmi; Paolo Pillastrini; Vincenzo Natale; Giuseppe Plazzi Journal: Front Neurol Date: 2018-08-24 Impact factor: 4.003
Authors: D Ophoff; M A Slaats; A Boudewyns; I Glazemakers; K Van Hoorenbeeck; S L Verhulst Journal: Eur J Pediatr Date: 2018-03-03 Impact factor: 3.183
Authors: Michel Lecendreux; Giuseppe Plazzi; Yves Dauvilliers; Carol L Rosen; Chad Ruoff; Jed Black; Rupa Parvataneni; Diane Guinta; Y Grace Wang; Emmanuel Mignot Journal: J Clin Sleep Med Date: 2022-09-01 Impact factor: 4.324